Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Abstract

The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10(-4)) after treatment is an independent predictor of progression-free survival (PFS), but not always of overall survival (OS). However, MRD level is a continuous variable, and the predictive value of the depth of tumor depletion was evaluated in 397 patients treated intensively in the Medical Research Council Myeloma IX study. There was a significant improvement in OS for each log depletion in MRD level (median OS was 1 year for ≥10%, 4 years for 1% to <10%, 5.9 years for 0.1% to <1%, 6.8 years for 0.01% to <0.1%, and more than 7.5 years for <0.01% MRD). MRD level as a continuous variable determined by flow cytometry independently predicts both PFS and OS, with approximately 1 year median OS benefit per log depletion. The trial was registered at www.isrctn.com as #68454111.

© 2015 by The American Society of Hematology.

Figures

Figure 1

Sequential improvements in PFS and OS for each log depletion in MRD level, as assessed by multiparameter flow cytometry. This effect is demonstrable in all patients ([A] PFS; [B] OS) as well as those achieving conventional CR ([C] PFS; [D] OS).